Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;12(4):394-402.
doi: 10.1177/1740774515579165. Epub 2015 Apr 7.

Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial

Liza Dawson  1 , Sam Garner  2 , Chuka Anude  3 , Paul Ndebele  4 , Shelly Karuna  5 , Renee Holt  6 , Gail Broder  5 , Jessica Handibode  7 , Scott M Hammer  8 , Magdalena E Sobieszczyk  8 ; NIAID HIV Vaccine Trials Network
Affiliations

Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial

Liza Dawson et al. Clin Trials. 2015 Aug.

Abstract

Background: The field of HIV prevention research has recently experienced some mixed results in efficacy trials of pre-exposure prophylaxis, vaginal microbicides, and HIV vaccines. While there have been positive trial results in some studies, in the near term, no single method will be sufficient to quell the epidemic. Improved HIV prevention methods, choices among methods, and coverage for all at-risk populations will be needed. The emergence of partially effective prevention methods that are not uniformly available raises complex ethical and scientific questions regarding the design of ongoing prevention trials.

Methods: We present here an ethical analysis regarding inclusion of pre-exposure prophylaxis in an ongoing phase IIb vaccine efficacy trial, HVTN 505. This is the first large vaccine efficacy trial to address the issue of pre-exposure prophylaxis, and the decisions made by the protocol team were informed by extensive stakeholder consultations. The key ethical concerns are analyzed here, and the process of stakeholder engagement and decision-making described.

Discussion: This discussion and analysis will be useful as current and future research teams grapple with ethical and scientific study design questions emerging with the rapidly expanding evidence base for HIV prevention.

Keywords: HIV prevention; HIV vaccine trials; clinical trial design; ethics; standard of prevention.

PubMed Disclaimer

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

References

    1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–2599. - PMC - PubMed
    1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505. - PMC - PubMed
    1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with Alvac and Aidsvax to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–2220. - PubMed
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–1174. - PMC - PubMed
    1. Global Campaign for Microbicides. Rethinking the Ethical Roadmap for Clinical Testing of Microbicides: Report on an International Consultation. Washington, DC: 2005.

Publication types

Grants and funding

LinkOut - more resources